Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/25/15  and contains information from public web pages and contributions from the ZoomInfo community.

Prof. Kaj Blennow

Wrong Prof. Kaj Blennow?

SCIENTIFIC ADVISORY BOARD Member

Phone: (610) ***-****  HQ Phone
Email: k***@***.com
Cerora Inc
116 Research Drive Suite 2207
Bethlehem , Pennsylvania 18015
United States

Company Description: Cerora, Inc. (CI) is a neuroscience diagnostics and biomarker technology company focused on creating practical technology to diagnose brain health. We deliver...   more
Background

Employment History

  • Professor of Clinical Neurochemistry
    Sahlgrenska University Hospital
  • Head, Clinical Neurochemistry Laboratory
    Sahlgrenska University Hospital
  • Professor In Clinical Neurochemistry
    University of Gothenburg
  • Professor - Neurochemical Pathophysiology and Diagnostics
    University of Gothenburg
  • Head of the Research Team On Neurochemical Pathogenesis and Diagnostics At the Department of Clinical Neuroscience
    University of Gothenburg , Sweden
  • Professor of Clinical Neurochemistry
    University of Gothenburg , Sweden
  • Chief Physician
    Neurochemistry Lab
  • Professor
    Neurochemistry Lab
  • Professor
    Sahlgren's University Hospital
  • Chief Physician In the Neurochemistry Laboratory
    Sahlgren's University Hospital
  • Professor
    Sahlgrenska Academy
  • Professor In Clinical Neurochemistry
    University of Göteborg
  • Head of the Department of Clinical Neuroscience
    University of Göteborg
  • Professor of Clinical Neurochemistry
    Lund University

Education

  • doctorate in psychiatry
    Göteborg University
  • Ph.D.
  • M.D.
  • medical degree
    Lund University
89 Total References
Web References
Kaj Blennow, MD, ...
cerora.com, 25 Dec 2015 [cached]
Kaj Blennow, MD, PhD
...
Kaj Blennow, MD, PhD
A recent review article in Alzheimer's ...
www.psychiatrictimes.com, 4 July 2014 [cached]
A recent review article in Alzheimer's and Dementia discusses the current state of cerebrospinal fluid-borne markers for Alzheimer disease.2 Tests that identify proteins in the CSF could be very specific to Alzheimer disease because the fluid directly interacts with brain tissue.3 According to first author, Kaj Blennow, MD, PhD, Professor of Clinical Neurochemistry at the Sahlgrenska University Hospital in Mölndal, Sweden, CSF is potentially better than blood since "a brain protein will be diluted in the larger blood volume, metabolized and degraded.
...
Blennow explains "They have been evaluated in hundreds of papers and very consistently show that more than 85%-90% of AD (and prodromal AD) cases have low Abeta42 and high total-tau and phospho-tau."
Levels of CSF amyloid-beta seem to decrease as post-mortem or biopsied brain levels increase, so it seems that the protein may deposit itself in the brain and while it correspondingly decreases in the fluid. CSF phosphorylated tau levels also correspond with the amount of neurofibrillary tangles found in a later autopsy. In addition, high levels of total tau in the CSF seem to indicate that mild cognitive impairment will quickly progress to full Alzheimer dementia. Unfortunately, the markers seem to be only good in the early stages of the disease. Blennow explains: "it seems that the AD biomarkers reach a plateau very early in disease progression, and thus do not change with progression."
Researchers may have another problem with developing a clinical test: the methods being used are not the same in every lab. The development of consistent assays is a high current priority in this field. According to Dr Blennow "what is needed is more work on standardization, both the analytical part and assay production, so that we can get uniform values between labs.
Alzheimer's Association International Conference | 2011 Awards
www.alz.org, 18 Sept 2011 [cached]
Dr. Kaj Blennow, M.D., Ph.D. Professor, Clinical Neurochemistry; Head, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital,
"This is one of the most ...
www.stresstherapysolutions.com, 12 Nov 2012 [cached]
"This is one of the most important pieces of direct evidence that individual persons have the disease and all the pathology many years before," said Dr. Kaj Blennow, a professor in clinical neurochemistry at the University of Gothenburg in Sweden, who was not involved in the research.
...
Dr. Blennow said that while researchers know that amyloid plaques plateau when people already have dementia, they did not know that the plateau appears to occur years before.
Kaj ...
news.thermo-brims.com, 5 Nov 2012 [cached]
Kaj Blennow
...
Kaj Blennow
Kaj Blennow is head of the research team on "Neurochemical Pathogenesis and Diagnostics" at the Dept. of Clinical Neuroscience, University of Gothenburg, Sweden. His major research interests are studies on ...
Comment on Kaj Blennow
Other People with the name "Blennow":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.